[
    [
        {
            "time": "2023-12-21",
            "original_text": "恒瑞医药董事长孙飘扬：医药企业应关注百姓未被满足的多样化临床需求",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "孙飘扬",
                    "临床需求",
                    "医药企业"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药董事长孙飘扬：医药企业应关注百姓未被满足的多样化临床需求",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-12-21",
            "original_text": "29亿美元重磅交易！高瓴重仓股领先下一个PD-1争夺战，恒瑞会跟进吗？",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "高瓴资本",
                    "PD-1",
                    "交易"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "29亿美元重磅交易！高瓴重仓股领先下一个PD-1争夺战，恒瑞会跟进吗？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-12-21",
            "original_text": "新药 | 瑛派药业ATR抑制剂IMP9064申报临床，阿斯利康、拜耳、恒瑞医药等积极布局",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "瑛派药业",
                    "ATR抑制剂",
                    "新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新药 | 瑛派药业ATR抑制剂IMP9064申报临床，阿斯利康、拜耳、恒瑞医药等积极布局",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-12-21",
            "original_text": "恒瑞医药：四纵一横的营销体系架构布局，使公司产品的推广更加专注、专业",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营销体系",
                    "产品推广"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：四纵一横的营销体系架构布局，使公司产品的推广更加专注、专业",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-12-21",
            "original_text": "恒瑞医药：公司未被美国列入实体清单中",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "实体清单",
                    "美国"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：公司未被美国列入实体清单中",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-12-21",
            "original_text": "业绩放缓 研发却丝毫不松懈 恒瑞医药创新药期待“开花结果”",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩放缓",
                    "研发",
                    "创新药"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "业绩放缓 研发却丝毫不松懈 恒瑞医药创新药期待“开花结果”",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-12-20",
            "original_text": "A股融资融券日报：两融余额减少40.23亿元（12月20日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额减少40.23亿元（12月20日）",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        }
    ]
]